<DOC>
	<DOCNO>NCT01582672</DOCNO>
	<brief_summary>This trial AGS-003 , study possible treatment Advanced Renal Cell Carcinoma . The purpose study determine whether overall survival ( OS ) benefit subject treat AGS-003 combination standard treatment versus subject treat standard treatment alone .</brief_summary>
	<brief_title>Phase 3 Trial Autologous Dendritic Cell Immunotherapy Plus Standard Treatment Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>This study investigate combination autologous ribonucleic acid ( RNA ) electroporated dendritic cell ( DC ) base immunotherapy , AGS-003 , plus standard treatment ( initiate sunitinib ) . The primary objective study determine median OS achieve combination compare OS result use active control ( standard treatment ) , population adult advance renal cell carcinoma ( RCC ) , nephrectomy indicated , remain metastatic disease .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Key Inclusion Criteria Tumor Collection : 1 . Diagnosis clinical sign advance RCC 2 . Scheduled cytoreductive partial nephrectomy Key Exclusion Criteria Tumor Collection : 1 . Known inability undergo sunitinib treatment currently label , due preexist medical condition 2 . Requirement systemic chronic immunosuppressive drug corticosteroid 3 . Evidence brain metastasis prior nephrectomy Key Inclusion Criteria Treatment Study : 1 . Advanced disease , histologically assessed RCC , predominantly clear cell histology 2 . Metastatic disease ( measurable nonmeasurable ) monitor throughout course study participation per RECIST 1.1 3 . Subjects candidate standard firstline therapy initiate sunitinib 4 . Time diagnosis treatment &lt; 1 year 5 . Karnofsky performance status ( KPS ) ≥ 70 % 6 . Life expectancy 6 month great 7 . Resolution acute toxic effect prior radiotherapy surgical procedure Grade ≤ 1 accord National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 8 . Adequate hematologic , renal , hepatic , coagulation function 9 . Negative serum pregnancy test female subject reproductive potential , agreement male female subject reproductive potential use reliable form contraception study 12 week last dose study drug 10 . Normal ECG clinically nonsignificant finding ( ) Screening 11 . Able abstain take prohibit drug , either prescription nonprescription , treatment phase study 12 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Key Exclusion Criteria Treatment Study : 1 . Prior systemic therapy ( include adjuvant neoadjuvant ) kind RCC , include immunotherapy , chemotherapy , hormonal , investigational therapy 2 . Prior history malignancy within precede 3 year , except adequately treat situ carcinoma nonmelanoma skin cancer , adequately treat early stage breast cancer , superficial bladder cancer , nonmetastatic prostate cancer normal PSA 3 . History known brain metastasis , spinal cord compression , carcinomatous meningitis , evidence brain leptomeningeal disease 4 . Patients 4 follow risk factor : 1 . Hgb &lt; LLN 2 . Corrected calcium &gt; 10.0 mg/dL 3 . KPS &lt; 80 % 4 . Neutrophils &gt; ULN 5 . Platelets &gt; ULN 5 . Planned elective surgical treatment postnephrectomy direct management RCC , within 28 day Visit 1 ( Week 0 ) 6 . NCI CTCAE Grade 3 hemorrhage &lt; 28 day Visit 1 ( Day 0 ) 7 . Clinically significant cardiovascular condition within 3 month prior Randomization 8 . Significant gastrointestinal abnormality 9 . Preexisting thyroid abnormality thyroid function maintain normal range medication 10 . Active autoimmune disease condition require chronic immunosuppressive therapy 11 . Clinically significant infection , include human immunodeficiency virus , syphilis , active hepatitis B C 12 . Current treatment investigational therapy another clinical trial 13 . Pregnancy breastfeed 14 . Any serious medical condition illness consider investigator constitute unwarranted high risk investigational treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RCC</keyword>
	<keyword>Kidney Cancer</keyword>
</DOC>